# CRLF2

Source: https://onco.cc/targets/crlf2/  
OnCo record `crlf2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CRLF2 (Cytokine receptor-like factor 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Acute lymphoblastic leukaemia and 2 more.

## Summary

Receptor for thymic stromal lymphopoietin (TSLP). Forms a functional complex with TSLP and IL7R which is capable of stimulating cell proliferation through activation of STAT3 and STAT5. Also activates JAK2.

CIViC holds 5 clinical evidence items and 0 assertions across 5 variants, naming Sirolimus and JAK Inhibitor I. Open Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.63, animal model 0.36, somatic mutation 0.80). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Lung Adenocarcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: cytokine receptor like factor 2; Cytokine receptor-like factor 2; CRL2; TSLPR
- Tags: cancer-genes-wave
- Symbol: CRLF2
- Class: tumor-suppressor
- Biology: Receptor for thymic stromal lymphopoietin (TSLP). Forms a functional complex with TSLP and IL7R which is capable of stimulating cell proliferation through activation of STAT3 and STAT5. Also activates JAK2. Implicated in the development of the haematopoietic system. Location: Cell membrane; Secreted (UniProt). Locus Xp22.3 and Yp11.3 (HGNC).
- Where found: Skin cancer: Open Targets association 0.56 with skin cancer (MONDO_0002898); Lung cancer: Open Targets association 0.53 with lung cancer (MONDO_0008903); Acute lymphoblastic leukaemia: CIViC evidence names this disease; Non-small-cell lung cancer: IntOGen driver in 1 cohort (LUAD); Melanoma: Open Targets association 0.52 with melanoma (MONDO_0005105)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 5 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: B-cell Adult Acute Lymphocytic Leukaemia; Childhood B-cell Acute Lymphoblastic Leukaemia.

## Sources

- HGNC HGNC:14281: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14281
- UniProt Q9HC73: https://www.uniprot.org/uniprotkb/Q9HC73/entry
- NCBI Gene 64109: https://www.ncbi.nlm.nih.gov/gene/64109
- Ensembl ENSG00000205755: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000205755

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/crlf2.json